CD274 and non-small cell lung carcinoma: Carbone et al. reported that nivolumab was associated with a higher response rate than chemotherapy in non-small-cell lung cancer (NSCLC) patients with higher TMB, regardless the expression status of PD-L1 (Carbone et al., 2017).